# Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

> **NCT00016263** · PHASE3 · COMPLETED · sponsor: **Genta Incorporated**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** dacarbazine

## Key facts

- **NCT ID:** NCT00016263
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** — (—)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016263, "Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00016263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*